Current Treatment Options in Neurology

, Volume 3, Issue 6, pp 495–506 | Cite as

Long-term medical treatment for Parkinson’s disease

  • John M. Bertoni
  • Jose-Luis Prendes
  • Pamela Sprenkle

Opinion statement

The authors of this paper view Parkinson’s disease (PD) as a clinically defined progressive syndrome of resting limb tremor, bradykinesia, muscle rigidity, and a shuffling unsteady gait that responds well to dopaminergic medications. Parkinson’s disease is a not a single entity, but rather a syndrome with diverse causes, with both genetic and environmental risk factors [1••]. The clinician’s concern is to rule out other entities, especially those having another specific treatment, and to give PD patients the best short- and long-term benefit, with the least possible unwanted side effects.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 2001, 56(suppl):S1-S88. This is an exceptional detailed up-to-date treatise on many aspects of PD, done by leading PD experts. It is very highly recommended for those who wish a more in depth understanding of PD.PubMedGoogle Scholar
  2. 2.
    Jankovic J: Parkinson’s disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 2000, 23:252–261.PubMedCrossRefGoogle Scholar
  3. 3.
    Reichmann H: Long-term treatment with dopamine agonists in idiopathic Parkinson’s disease. J Neurol 2000, 247(suppl):17–19.CrossRefGoogle Scholar
  4. 4.
    Lang AE: Surgery for Parkinson’s disease: a critical evaluation of the state of the art. Arch Neurol 2000, 57:1118–1125.PubMedCrossRefGoogle Scholar
  5. 5.
    Krack P, Poepping M, Weinert D, et al.: Thalamic, pallidal, or subthalamic surgery for Parkinson’s disease? J Neurol 2000, 247(suppl):122–134.Google Scholar
  6. 6.
    Parkinson’s Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease: the Parkinson’s Study Group. N Engl J Med 1993, 328:176–183.CrossRefGoogle Scholar
  7. 7.
    Carter JH, Nutt JG, Woodward WR, et al.: Amount and distribution of dietary protein affects chemical response to levodopa in Parkinson’s disease. Neurology 1989, 39:552–556.PubMedGoogle Scholar
  8. 8.
    Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality, 1967. Neurology 1998, 50:318–334.PubMedGoogle Scholar
  9. 9.
    Jankovic J, Tolosa E: Parkinson’s Disease and Movement Disorders, edn 3. Baltimore: Williams and Wilkins; 1998.Google Scholar
  10. 10.
    Drug Topics Red Book. Montvale, NJ: Medical Economics Co., Inc.; 2001.Google Scholar
  11. 11.
    Merello M, Lees AJ, Webster R, et al.: Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatr 1994, 57:186–189.PubMedGoogle Scholar
  12. 12.
    Adler CH, Singer C, O’Brien C, et al.: Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson’s disease treated with levodopa-carbidopa: Tolcapone Fluctuator Study Group III. Arch Neurol 1998, 55:1089–1095.PubMedCrossRefGoogle Scholar
  13. 13.
    Shoulson I: DATATOP: a decade of neuroprotective inquiry. Parkinson’s Study Group: deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol 1998, 44(auppl):S160–166.PubMedGoogle Scholar
  14. 14.
    Schwab RS, England AC, Poskanzer DC, Young RR: Amantadine in the treatment of Parkinson’s disease. JAMA 1969, 208:1168–1170.PubMedCrossRefGoogle Scholar
  15. 15.
    Mann DC, Pearce LA, Waterbury LD: Amantadine for Parkinson’s disease. Neurology 1971, 21:958–962.PubMedGoogle Scholar
  16. 16.
    Parkes JD, Baxter RC, Curzon G, et al.: Treatment of Parkinson’s disease with amantadine and levodopa: a one-year study. Lancet 1971, 1:1083–1086.PubMedCrossRefGoogle Scholar
  17. 17.
    Luginger E, Wenning GK, Bosch S, Poewe W: Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2000, 15:873–878.PubMedCrossRefGoogle Scholar
  18. 18.
    Koller WC: Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986, 43:126–127.PubMedGoogle Scholar
  19. 19.
    Alarcon F, Cevallos N, Lees AJ: Does combined levodopa and bromocriptine therapy in Parkinson’s disease prevent late motor complications? Eur J Neurol 1998, 5:255–263.PubMedCrossRefGoogle Scholar
  20. 20.
    Hely MA, Morris JG, Reid WG, et al.: The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903–910.PubMedCrossRefGoogle Scholar
  21. 21.
    Olanow CW, Fahn S, Muenter M, et al.: A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994, 9:40–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Boas J, Worm-Petersen J, Dupont E, et al.: The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label crossover study. Eur J Neurol 1996, 3:44–49.Google Scholar
  23. 23.
    Pinter MM, Pogarell O, Oertel WH: Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomized, multicentre study. J Neurol Neurosurg Psychiatry 1999, 66:436–441.PubMedGoogle Scholar
  24. 24.
    Shannon KM, Bennett JP, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease: the Pramipexole Study Group. Neurology 1997, 49:724–728.PubMedGoogle Scholar
  25. 25.
    Kunig G, Pogarell O, Moller JC, et al.: Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin Neuropharmacol 1999, 22:301–305.PubMedGoogle Scholar
  26. 26.
    Clarke CE, Speller JM, Clarke JA: Pramipexole for levodopa-induced complications in Parkinson’s disease (Cochrane Review). In The Cochrane Library. Oxford: Update Software Press; 2001.Google Scholar
  27. 27.
    Korczyn AD, Brunt ER, Larsen JP, et al.: A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology 1999, 53:364–370.PubMedGoogle Scholar
  28. 28.
    Lieberman A, Olanow CW, Sethi K, et al.: A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease: Ropinirole Study Group. Neurology 1998, 51:1057–1062.PubMedGoogle Scholar
  29. 29.
    Clarke CE, Deane KHO: Ropinirole for levodopa-induced complications in Parkinson’s disease (Cochrane Review). In The Cochrane Library. Oxford: Update Software Press; 2001.Google Scholar
  30. 30.
    Clarke CE, Deane KHO: Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson’s disease (Cochrane Review). In The Cochrane Library. Oxford: Update Software Press; 2001.Google Scholar
  31. 31.
    Thompson AJ, Playford ED: Rehabilitation for patients with Parkinson’s disease. Lancet 2001, 357:410–411. Commentary assessing the value of physical rehabilitation in Parkinson’s disease, largely based upon the conclusions of six Cochrane reviews and the problems cited therein.PubMedCrossRefGoogle Scholar
  32. 32.
    de Goede CJT, Keus SHJ, Kwakkel G, Wagenaar RC: The effects of physical therapy in Parkinson’s disease: a research synthesis. Arch Phys Med Rehabil 2001, 82:509–515. Meta-analysis of data from 1996 to 1999 shows significant effects on ADLs, stride length, and walking speed, but not neurologic symptoms. The small number of studies and their methodological shortcomings are acknowledged.PubMedCrossRefGoogle Scholar
  33. 33.
    Bridgewater KJ, Sharpe MH: Aerobic exercise and early Parkinson’s disease. J Neurol Rehabil 1996, 10:233–241.Google Scholar
  34. 34.
    Morris ME: Movement disorders in people with Parkinson’s disease: a model for physical therapy. Phys Ther 2000, 80:578–597. Comprehensive review with author’s perspective. This is recommended for detailed physical therapy goals appropriate for different Hoehn and Yahr stages.PubMedGoogle Scholar
  35. 35.
    Deane KHO, Whurr R, Playford ED, et al.: Speech and language therapy for dysarthria in Parkinson’s disease (Cochrane Review). In In The Cochrane Library. Oxford: Update Software Press; 2001.Google Scholar
  36. 36.
    Montgomery EB, Lieberman A, Singh G, Fries JF: Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial. Am J Med 1994, 97:429–435.PubMedCrossRefGoogle Scholar
  37. 37.
    Waters CH: Diagnosis and Management of Parkinson’s Disease, edn 2. Caddo, OK: Professional Communications, Inc.: 1999:138.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • John M. Bertoni
    • 1
  • Jose-Luis Prendes
    • 1
  • Pamela Sprenkle
    • 1
  1. 1.Department of NeurologyCreighton University School of MedicineOmahaUSA

Personalised recommendations